2008 Genitourinary Cancers Symposium
A Multidisciplinary Approach

Draft Program Agenda

---

Prostate Cancer – Thursday, February 14, 2008

---

Exhibit Hall Open
7:00 AM – 6:00 PM

Breakfast
7:00 AM – 8:00 AM
Continental Breakfast Provided

Welcome
8:00 AM – 8:15 AM

General Session I: Translational Science in Prostate Cancer
8:15 AM – 9:45 AM
Moderator: Robert Getzenberg, PhD – Johns Hopkins Medical Institutions

Nutrition and Prostate Cancer
June Chan, ScD – University of California, San Francisco

Prostatic Stem Cell: Insight into Tumor Initiation
John T. Isaacs, PhD – Johns Hopkins Medical Institutions

The Role of MicroRNA in Prostate Tumor Biology
Colleen C. Nelson, PhD – The Prostate Centre at Vancouver General Hospital

Question and Answer Session

Oral Presentation of Topic-Related Selected Abstracts (to be integrated into session)

Break
9:45 AM – 10:00 AM

General Session II: Androgen Axis as A Therapeutic Target – Past, Present, and Future
10:00 AM – 11:30 AM
Moderators: Edward P. Gelmann, MD – Columbia University
Chris Parker, MD, MRCP, FRCR – Institute of Cancer Research/Royal Marsden Hospital

Androgen Receptor Reactivation after Androgen Deprivation Therapy
Steven Balk, MD, PhD – Beth Israel Deaconess Medical Center

Secondary Androgen Deprivation: Treating the Prostate-Speific Antigen or the Patient
William K. Oh, MD – Dana-Farber Cancer Institute

Potential Targets in Patients with Androgen Independent Disease
Edward P. Gelmann, MD – Columbia University

Question and Answer Session

Oral Presentation of Topic-Related Selected Abstracts

General Poster Session A: Prostate Cancer
11:30 AM – 12:30 PM
Box Lunches Provided

Oral Abstract Presentation Session A: Prostate Cancer
12:30 PM – 1:30 PM
Moderator: Martin Gleave, MD - Vancouver Hospital and Health Sciences Centre

Break
1:30 PM – 1:45 PM

General Session III: Screening and Treatment in the Elderly and Frail
1:45 PM – 3:15 PM
Moderators: Anthony D’Amico, MD, PhD – Brigham and Women’s Hospital
Freddie Hamdy, MD, FRCSEd (Urol), FMedSci – University of Sheffield

Prostate-Specific Antigen Screening Among Elderly Men with Limited Life Expectancies
Badrinath R. Konety, MD, MBA – University of California, San Francisco

Are We Under-Treating the Elderly Male?
Katrina Armstrong, MD – University of Pennsylvania

Side Effects of Local Therapy in the Elderly Male
Martin G. Sanda, MD – Beth Israel Deaconess Medical Center

Metabolic Syndrome in America: Implications for Treatment
Stephen J. Freedland, MD – Duke University Medical Center

Interactive Panel Discussion and Audience Question and Answer Session
Anthony D’Amico and Freddie Hamdy

Break
3:15 PM – 3:30 PM

General Session IV: Treatment of the Primary Tumor in High-Risk Nonmetastatic Prostate Cancer
3:30 PM – 5:00 PM
Moderators: Juanita M. Crook, MD – Princess Margaret Hospital
Robert Dreicer, MD, FACP – Cleveland Clinic Foundation

Radiation Therapy: How Much Androgen Deprivation Therapy is Enough?
Howard Sandler, MD – University of Michigan Medical Center

Brachytherapy: More is Better
Alvaro A. Martinez, MD, FACR – William Beaumont Hospital

Surgical Perspectives in High-Risk Prostate Cancer
Mitchell C. Benson, MD – Columbia University

Question and Answer Session

Oral Presentation of Topic-Related Selected Abstracts

General Poster Session B: Prostate Cancer
5:00 PM – 6:00 PM
Wine and Cheese Reception

---

Prostate, Testis, and Bladder Cancers – Friday, February 15, 2008

---

Best of Journals Session: Prostate Cancer
7:00 AM – 8:00 AM

Exhibit Hall Open
7:00 AM – 6:00 PM

Breakfast
7:00 AM – 8:00 AM
Continental Breakfast Provided

Welcome
8:00 AM – 8:15 AM

General Session V: Anticipating Failure in the Advanced Patient
8:15 AM – 9:45 AM
Moderators: Deborah Kuban, MD – M. D. Anderson Cancer Center
James E. Montie, MD – University of Michigan Medical Center

High-Risk Disease after Radical Retropubic Prostatectomy: The Case for Adjuvant External Beam Radiation Therapy
Anthony L. Zietman, MD – Massachusetts General Hospital

High-Risk Disease after Radical Retropubic Prostatectomy: The Case for Systemic Treatment
Adam Stuart Kibel, MD – Washington University School of Medicine

Question and Answer Session

Management of Post-Docetaxel Treatment
Tomasz M. Beer, MD – Oregon Health and Science University

Novel Therapeutics: What’s on the Horizon?
Michael A. Carducci, MD – Johns Hopkins Kimmel Cancer Center

Questions and Answer Session

Oral Presentation of Topic-Related Selected Abstracts

Break
9:45 AM – 10:00 AM

General Session VI: Controversies in Testis Cancer
10:00 AM – 11:30 AM
Moderators: Eric A. Klein, MD – Cleveland Clinic Foundation
Joel Sheinfeld, MD – Memorial Sloan-Kettering Cancer Center

Current Concepts and Controversies in the Management of Clinical Stage 1 Seminoma – Treatment
Gillian Duchesne, MBChB, FRCR, MD, FRANZCR – Peter MacCallum Cancer Center

Current Concepts and Controversies in the Management of Clinical Stage 1 Seminoma – Surveillance
Padraig R. Warde, MB, FRCPC – Princess Margaret Hospital

Current Concepts and Controversies in the Management of Clinical Stage 1 Nonseminoma – Treatment
Craig R. Nichols, MD – Earle A. Chiles Research Institute

Current Concepts and Controversies in the Management of Clinical Stage 1 Nonseminoma – Surveillance
Andrew J. Stephenson, MD – Cleveland Clinic Foundation

Questions and Answer Session

Case Discussions: Surgery or No Surgery after A Radiographic Response? Role of Adjuvant Chemotherapy
Moderators : Joel Sheinfeld and Eric Klein
Discussants : Gillian Duchesne, Padraig Warde, Craig Nichols, and Andrew Stephenson

General Poster Session C: Prostate Cancer
11:30 AM – 12:30 PM
Box Lunches Provided

Fellows, Residents, and Junior Faculty Lunch Session
11:30 AM – 12:30 PM

Oral Abstract Presentation Session B: Testis and Bladder Cancer
12:30 PM – 1:30 PM
Moderator: Gillian Duchesne , MBChB, FRCR, MD, FRANZCR – Peter MacCallum Cancer Center

Break
1:30 PM – 1:45 PM

General Session VII: Translational Science in Bladder Cancer
1:45 PM – 3:00 PM
Moderators: Colin P. N. Dinney, MD – M. D. Anderson Cancer Center
Maha Hussain, MD, FACP – University of Michigan

Molecular Biology of Bladder Cancer
Carlos Cordon-Cardo, MD, PhD – Columbia University

Biomarkers of Tumor Staging, Prognosis, and Treatment Response
Dan Theodorescu, MD, PhD – University of Virginia

Novel Molecular Targets in Bladder Cancer
Christopher Sweeney, MBBS – Royal Adelaide Hospital Cancer Centre

Question and Answer Session

Break
3:00 PM – 3:15 PM

General Session VIII: Walking the Tightrope in Bladder Cancer: Too Much versus Too Little
3:15 PM – 5:00 PM
Moderators: Ralph deVere White, MB, BCh, BAO – University of California Davis School of Medicine
Mary K. Gospodarowicz, MD – Princess Margaret Hospital

Bacillus Calmelte Guerin Failure (High-Risk Superficial Disease)
Michael A. O’Donnell, MD, FACS – University of Iowa

Systemic Chemotherapy for Advanced Urothelial Cancer
Primo N. Lara, MD – University of California Davis Cancer Center

Sequential Therapy in Bladder Cancer
William U. Shipley, MD, FACR – Massachusetts General Hospital

Novel Trial Design Consideration for High-Risk Local Disease (Invasive and Noninvasive)
Walter M. Stadler, MD – University of Chicago

Case Discussion: Systemic Chemotherapy in Multimodal Treatment (Adjuvant/Neoadjuvant)
Michael S. Cookson, MD – Vanderbilt-Ingram Cancer Center
Jorge A. Garcia, MD – Cleveland Clinic Taussig Cancer Center
Mary K. Gospodarowicz, MD – Princess Margaret Hospital

General Poster Session D: Bladder and Testis Cancer
5:00 PM – 6:00 PM
Wine and Cheese Reception

---

Renal Cell Cancer – Saturday, February 16, 2008

---

Best of Journals Session: Renal Cell Cancer
7:00 AM – 8:00 AM

Breakfast
7:00 AM – 8:00 AM
Continental Breakfast Provided

Welcome
8:00 AM – 8:15 AM

General Session IX: Translational Science in Renal Cell Cancer
8:15 AM – 9:45 AM
Moderators: Daniel J. George, MD – Duke University Medical Center
Cora Sternberg, MD, FACP – San Camillo Forlanini Hospital

Complexities of Hypoxia-Inducible Factor Biology
William G. Kaelin, MD – Dana-Farber Cancer Institute

Mechanisms of Vascular Endothelial Growth Factor Inhibitor Resistance
Michael B. Atkins, MD – Beth Israel Deaconess Medical Center

Mechanisms of Action for mTOR Inhibition in Renal Cell Cancer
James Brugarolas, MD, PhD – University of Texas Southwestern Medical Center

Prognostic and Functional Significance of the B7 Family in the Biology of Renal Cell Cancer
Eugene D. Kwon, MD – Mayo Clinic

Question and Answer Session

Break
9:45 AM – 10:00 AM

General Session X: Optimal Management of Stage 1 Renal Cell Cancer
10:00 AM – 11:30 AM
Moderators: Jeffrey A. Cadeddu, MD – University of Texas Southwestern Medical Center
Robert G. Uzzo, MD, FACS – Fox Chase Cancer Center

Case Introduction
Jeffrey A. Cadeddu, MD – University of Texas Southwestern Medical Center

Radiofrequency Ablation (RFA) Discussion
Alice Gillams, MD – Royal Free and University College Medical School

Cryoablation Discussion
Inderbir Gill, MD, MCh – Cleveland Clinic Foundation

Open Partial Nephrectomy Discussion
Robert G. Uzzo, MD, FACS – Fox Chase Cancer Center

Laparoscopic Partial Nephrectomy Discussion
Peter A. Pinto, MD – National Cancer Institute

Active Surveillance
Michael A. S. Jewett, MD, FRCSC – Princess Margaret Hospital

Question and Answer Session

General Poster Session E: Renal Cell Cancer
11:30 AM – 12:30 PM
Box Lunches Provided

Oral Abstract Presentation Session C: Renal Cell Cancer
12:30 PM – 1:30 PM
Moderators: Ronald M. Bukowski, MD – Cleveland Clinic Foundation
Tim Eisen, PhD – University of Cambridge

Break
1:30 PM – 1:45 PM

General Session XI: Surgery, Sequencing, and Paradigm Shifts in the Era of Targeted Therapy
1:45 PM – 3:15 PM
Moderators: Ronald M. Bukowski, MD – Cleveland Clinic Foundation
Christopher G. Wood, MD, FACS – M. D. Anderson Cancer Center

Case 1 Introduction
Christopher G. Wood, MD, FACS - M. D. Anderson Cancer Center

Case 1: Metastatic Renal Cell Cancer at Presentation: Rationale for Debulking Nephrectomy in the Vascular Endothelial Growth Factor Targeted Therapy Era
Steven Campbell, MD, PhD – Cleveland Clinic Foundation

Case 1: Metastatic Renal Cell Cancer at Presentation: Rationale for Systemic Vascular Endothelial Growth Factor Targeted Therapy Before Surgery
Eric Jonasch, MD – M. D. Anderson Cancer Center

Question and Answer Session

Case 2 Introduction
Ronald M. Bukowski, MD - Cleveland Clinic Foundation

Case 2: Management Approach #1 – Low-Risk Metastatic Renal Cell Cancer Patient Presentation
David McDermott, MD – Beth Israel Deaconess Medical Center

Case 2: Management Approach #2 – Rationale and Data (Chronic Management)
Bernard J. Escudier, MD – Institute Gustave-Roussy

Role of Metastasectomy in Metastatic Renal Cell Cancer
David A. Swanson, MD, FACS – M. D. Anderson Cancer Center

Question and Answer Session

Break
3:15 PM – 3:30 PM

General Session XII: Cautionary Insights for Targeted Therapy
3:30 PM – 5:00 PM
Moderators: Tim Eisen, PhD – University of Cambridge
Bernard J. Escudier, MD – Institute Gustave-Roussy

Cardiovascular Complications with Vascular Endothelial Growth Factor Inhibitors: Underlying Biologic Mechanisms and Risk
Jean-Bernard Durand, MD – M. D. Anderson Cancer Center

Sequential Drug Therapy: Which Patients and What Order of Agents?
Thomas E. Hutson, DO, PharmD – Texas Oncology

Combination Drug Therapy: Pitfalls and Promise with Targeted Agents
Robert J. Motzer, MD – Memorial Sloan-Kettering Cancer Center

Questions and Answer Session

Oral Presentation of Topic-Related Selected Abstracts (to be integrated into session)